Lund, Sweden, November 5, 2008 - MIP Technologies AB announced today that it has received funding for a 4 year project which includes funding for a 3 year PhD position. The EU funded project, Nemopur, under the European Commission’s Marie Curie Initial Training network within the 7th Framework Programme, aims to offer a powerful and unique solution to the purification of active pharmaceutical ingredients (APIs) by combining Organic Solvent Nanofiltration (OSN) with MIPs. The project focus will be on the removal of contaminant organic compounds from APIs.
The network consists of 3 universities, 2 small and medium sized companies, including MIP Technologies and the four end-users; Hovione SA, UCB Pharma SA, GlaxoSmithKline Ltd and Lonza Ltd, who will provide input on the choice of purification systems and validation of the purification methods developed.
In the development and manufacturing of APIs and their intermediates, purification consumes the bulk of the processing time and cost. Burgeoning technological advances in analysis, which make detection of impurities at ever lower levels possible, exacerbates the time and cost demands. At the same time, there is a growing expectation among patients regarding the efficacy, safety and purity of medicines. These trends have created an urgent need for new molecular purification technologies in pharmaceutical production.
The overall goal of Nemopur is to make a paradigm shift in the approach to purifying API intermediates. An essential feature of this project will be the interdisciplinary nature of the partners and the fact that they bring inter-sectorial competence to the network, spanning academic, technology SME, and end user sectors.
“We are very excited to be part of this EU-network. It is our belief that MIPs constitute a powerful technique for highly selective removal of impurities from API solutions,” said Dr Ecevit Yilmaz, chief technology officer at MIP Technologies.
“Participating in this research program will further strengthen MIP Technologies by facilitating the creation of novel MIP materials for large scale processes, particularly important in the pharma and biopharma industries” said Anthony Rees, CEO at MIP Technologies.
About MIP Technologies:
MIP Technologies AB is a world-leading company in the development of molecularly imprinted polymers (MIPs). The Company is a pioneer in the commercial applications of MIPs, holds important patents and maintains cutting-edge research activities in this area. The Company’s mission is to provide innovative products based on molecularly imprinted polymers that serve industry’s needs in analytical, preparative and process scale ‘selective separations’. The Company has environmental permission to produce MIP phases at the 500 kg level and is well placed to develop large scale separation solutions for its customers. Currently, the Company develops analytical separation products (e.g. SPE) and has multiple custom process scale projects in place with several blue chip companies. MIP Technologies has its headquarters in Lund, Sweden. For more information about MIP Technologies AB visit www.miptechnologies.com
Cautionary Statement:
This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies’ expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company’s operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
